209 related articles for article (PubMed ID: 32565927)
1. PBX1 is a valuable prognostic biomarker for patients with breast cancer.
Ao X; Ding W; Ge H; Zhang Y; Ding D; Liu Y
Exp Ther Med; 2020 Jul; 20(1):385-394. PubMed ID: 32565927
[TBL] [Abstract][Full Text] [Related]
2. Coexpression of PBX1 and EMP2 as Prognostic Biomarkers in Estrogen Receptor-Negative Breast Cancer via Data Mining.
Qiu Y; Lu G; Wu Y
J Comput Biol; 2020 Oct; 27(10):1509-1518. PubMed ID: 32216630
[TBL] [Abstract][Full Text] [Related]
3. High WDR34 mRNA expression as a potential prognostic biomarker in patients with breast cancer as determined by integrated bioinformatics analysis.
Hu DJ; Shi WJ; Yu M; Zhang L
Oncol Lett; 2019 Sep; 18(3):3177-3187. PubMed ID: 31452794
[TBL] [Abstract][Full Text] [Related]
4. FoxM1 is a promising candidate target in the treatment of breast cancer.
Lu XF; Zeng D; Liang WQ; Chen CF; Sun SM; Lin HY
Oncotarget; 2018 Jan; 9(1):842-852. PubMed ID: 29416660
[TBL] [Abstract][Full Text] [Related]
5. Prognostic Significance of Prostaglandin-Endoperoxide Synthase-2 Expressions in Human Breast Carcinoma: A Multiomic Approach.
Saindane M; Rallabandi HR; Park KS; Heil A; Nam SE; Yoo YB; Yang JH; Yun IJ
Cancer Inform; 2020; 19():1176935120969696. PubMed ID: 33223820
[TBL] [Abstract][Full Text] [Related]
6.
Martinou EG; Moller-Levet CS; Angelidi AM
Am J Cancer Res; 2022; 12(2):585-600. PubMed ID: 35261789
[TBL] [Abstract][Full Text] [Related]
7. CXCR4 and CXCR3 are two distinct prognostic biomarkers in breast cancer: Database mining for CXCR family members.
Guo K; Feng G; Yan Q; Sun L; Zhang K; Shen F; Shen M; Ruan S
Mol Med Rep; 2019 Dec; 20(6):4791-4802. PubMed ID: 31702806
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of lipid metabolism genes and PBX1 in the contralateral breasts of women with estrogen receptor-negative breast cancer.
Wang J; Shidfar A; Ivancic D; Ranjan M; Liu L; Choi MR; Parimi V; Gursel DB; Sullivan ME; Najor MS; Abukhdeir AM; Scholtens D; Khan SA
Int J Cancer; 2017 Jun; 140(11):2484-2497. PubMed ID: 28263391
[TBL] [Abstract][Full Text] [Related]
9. The estrogen receptor coactivator AIB1 is a new putative prognostic biomarker in ER-positive/HER2-negative invasive lobular carcinoma of the breast.
Narbe U; Sjöström M; Forsare C; Bendahl PO; Alkner S; Leeb-Lundberg LMF; Lövgren K; Rydén L; Ingvar C; Fernö M
Breast Cancer Res Treat; 2019 Jun; 175(2):305-316. PubMed ID: 30796653
[TBL] [Abstract][Full Text] [Related]
10. Systematic analysis of the expression and prognosis relevance of FBXO family reveals the significance of FBXO1 in human breast cancer.
Liu Y; Pan B; Qu W; Cao Y; Li J; Zhao H
Cancer Cell Int; 2021 Feb; 21(1):130. PubMed ID: 33622332
[TBL] [Abstract][Full Text] [Related]
11. Expression of Protein 4.1 Family in Breast Cancer: Database Mining for 4.1 Family Members in Malignancies.
Feng G; Guo K; Yan Q; Ye Y; Shen M; Ruan S; Qiu S
Med Sci Monit; 2019 May; 25():3374-3389. PubMed ID: 31063460
[TBL] [Abstract][Full Text] [Related]
12. Prognostic values of the inhibitor of DNA‑binding family members in breast cancer.
Zhou XL; Zeng D; Ye YH; Sun SM; Lu XF; Liang WQ; Chen CF; Lin HY
Oncol Rep; 2018 Oct; 40(4):1897-1906. PubMed ID: 30066902
[TBL] [Abstract][Full Text] [Related]
13. Expressions and prognostic values of the
Liu ZL; Bi XW; Liu PP; Lei DX; Wang Y; Li ZM; Jiang WQ; Xia Y
Cancer Manag Res; 2018; 10():3521-3532. PubMed ID: 30271201
[No Abstract] [Full Text] [Related]
14. Long non-coding RNA00544 serves as a potential novel predictive and prognostic marker for HR+ HER2- subtype breast cancer.
Liu L; Chi Y; Chen J; Xue J; Deng L; Huang N; Shao J; Wu J
Sci Rep; 2017 Sep; 7(1):12382. PubMed ID: 28959047
[TBL] [Abstract][Full Text] [Related]
15. FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.
Badve S; Turbin D; Thorat MA; Morimiya A; Nielsen TO; Perou CM; Dunn S; Huntsman DG; Nakshatri H
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4415-21. PubMed ID: 17671124
[TBL] [Abstract][Full Text] [Related]
16. Comparisons of p53, KI67 and BRCA1 expressions in patients with different molecular subtypes of breast cancer and their relationships with pathology and prognosis.
Li Y; Zhang X; Qiu J; Pang T; Huang L; Zeng Q
J BUON; 2019; 24(6):2361-2368. PubMed ID: 31983107
[TBL] [Abstract][Full Text] [Related]
17. GATA3 and TRPS1 are distinct biomarkers and prognostic factors in breast cancer: database mining for GATA family members in malignancies.
Lin HY; Zeng D; Liang YK; Wei XL; Chen CF
Oncotarget; 2017 May; 8(21):34750-34761. PubMed ID: 28423734
[TBL] [Abstract][Full Text] [Related]
18. PBX1 Participates in Estrogen-mediated Bladder Cancer Progression and Chemo-resistance Affecting Estrogen Receptors.
Zhao Y; Che J; Tian A; Zhang G; Xu Y; Li S; Liu S; Wan Y
Curr Cancer Drug Targets; 2022; 22(9):757-770. PubMed ID: 35422219
[TBL] [Abstract][Full Text] [Related]
19. Prognostic values of distinct CBX family members in breast cancer.
Liang YK; Lin HY; Chen CF; Zeng D
Oncotarget; 2017 Nov; 8(54):92375-92387. PubMed ID: 29190923
[TBL] [Abstract][Full Text] [Related]
20. The transcriptional STAT3 is a potential target, whereas transcriptional STAT5A/5B/6 are new biomarkers for prognosis in human breast carcinoma.
Wu HT; Liu J; Li GW; Shen JX; Huang YT
Oncotarget; 2017 May; 8(22):36279-36288. PubMed ID: 28422733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
